Medtronic PLC Cash Flow Conversion Efficiency
Medtronic PLC cash flow conversion efficiency. Based on the latest financial reports, Medtronic PLC (2M6) has a cash flow conversion efficiency ratio of 0.051x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.57 Billion ≈ $3.01 Billion USD) by net assets (€50.07 Billion ≈ $58.54 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medtronic PLC (1990–2026)
Cash flow conversion efficiency of Medtronic PLC from 1990 to 2026. This chart illustrates how Medtronic PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Medtronic PLC for real-time trading data and today's change.
Medtronic PLC Cash Flow Conversion Ratio Explained
Medtronic PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medtronic PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medtronic PLC ranked by their cash flow conversion efficiency. Also see 2M6 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zijin Mining Group Co Ltd Class A
SHG:601899
|
0.106x |
|
Investor AB ser. B
ST:INVE-B
|
0.012x |
|
China Petroleum & Chemical Corp Class A
SHG:600028
|
0.054x |
|
Postal Savings Bank of China Co Ltd
SHG:601658
|
0.009x |
|
Comcast Corp
NASDAQ:CMCSA
|
0.078x |
|
Sherwin-Williams Co
NYSE:SHW
|
0.284x |
|
Ping An Insurance Group Co of China Ltd
SHG:601318
|
0.001x |
|
MercadoLibre Inc.
NASDAQ:MELI
|
0.285x |
Annual Cash Flow Conversion Efficiency for Medtronic PLC (1990–2026)
The table below shows the annual cash flow conversion efficiency of Medtronic PLC from 1990 to 2026. Review cash generation quality of Medtronic PLC to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-04-30 | €50.07 Billion ≈ $58.54 Billion |
€7.33 Billion ≈ $8.57 Billion |
0.146x | +0.28% |
| 2025-04-30 | €48.26 Billion ≈ $56.42 Billion |
€7.04 Billion ≈ $8.24 Billion |
0.146x | +8.44% |
| 2024-04-30 | €50.42 Billion ≈ $58.95 Billion |
€6.79 Billion ≈ $7.93 Billion |
0.135x | +15.16% |
| 2023-04-30 | €51.66 Billion ≈ $60.40 Billion |
€6.04 Billion ≈ $7.06 Billion |
0.117x | -16.11% |
| 2022-04-30 | €52.72 Billion ≈ $61.64 Billion |
€7.35 Billion ≈ $8.59 Billion |
0.139x | +15.22% |
| 2021-04-30 | €51.60 Billion ≈ $60.33 Billion |
€6.24 Billion ≈ $7.30 Billion |
0.121x | -14.96% |
| 2020-04-30 | €50.87 Billion ≈ $59.47 Billion |
€7.23 Billion ≈ $8.46 Billion |
0.142x | +1.90% |
| 2019-04-30 | €50.21 Billion ≈ $58.70 Billion |
€7.01 Billion ≈ $8.19 Billion |
0.140x | +51.41% |
| 2018-04-30 | €50.82 Billion ≈ $59.42 Billion |
€4.68 Billion ≈ $5.48 Billion |
0.092x | -32.46% |
| 2017-04-30 | €50.42 Billion ≈ $58.94 Billion |
€6.88 Billion ≈ $8.04 Billion |
0.136x | +35.54% |
| 2016-04-30 | €51.83 Billion ≈ $60.59 Billion |
€5.22 Billion ≈ $6.10 Billion |
0.101x | +9.33% |
| 2015-04-30 | €53.23 Billion ≈ $62.23 Billion |
€4.90 Billion ≈ $5.73 Billion |
0.092x | -63.89% |
| 2014-04-30 | €19.44 Billion ≈ $22.73 Billion |
€4.96 Billion ≈ $5.80 Billion |
0.255x | -2.48% |
| 2013-04-30 | €18.67 Billion ≈ $21.83 Billion |
€4.88 Billion ≈ $5.71 Billion |
0.262x | +2.16% |
| 2012-04-30 | €17.11 Billion ≈ $20.01 Billion |
€4.38 Billion ≈ $5.12 Billion |
0.256x | +9.27% |
| 2011-04-30 | €15.97 Billion ≈ $18.67 Billion |
€3.74 Billion ≈ $4.37 Billion |
0.234x | -17.03% |
| 2010-04-30 | €14.63 Billion ≈ $17.10 Billion |
€4.13 Billion ≈ $4.83 Billion |
0.282x | -6.42% |
| 2009-04-30 | €12.85 Billion ≈ $15.02 Billion |
€3.88 Billion ≈ $4.53 Billion |
0.302x | -0.22% |
| 2008-04-30 | €11.54 Billion ≈ $13.49 Billion |
€3.49 Billion ≈ $4.08 Billion |
0.302x | +11.44% |
| 2007-04-30 | €10.98 Billion ≈ $12.83 Billion |
€2.98 Billion ≈ $3.48 Billion |
0.271x | +15.35% |
| 2006-04-30 | €9.38 Billion ≈ $10.97 Billion |
€2.21 Billion ≈ $2.58 Billion |
0.235x | -12.80% |
| 2005-04-30 | €10.45 Billion ≈ $12.22 Billion |
€2.82 Billion ≈ $3.30 Billion |
0.270x | -13.94% |
| 2004-04-30 | €9.08 Billion ≈ $10.61 Billion |
€2.85 Billion ≈ $3.33 Billion |
0.314x | +19.28% |
| 2003-04-30 | €7.91 Billion ≈ $9.24 Billion |
€2.08 Billion ≈ $2.43 Billion |
0.263x | +6.30% |
| 2002-04-30 | €6.43 Billion ≈ $7.52 Billion |
€1.59 Billion ≈ $1.86 Billion |
0.247x | -25.62% |
| 2001-04-30 | €5.51 Billion ≈ $6.44 Billion |
€1.83 Billion ≈ $2.14 Billion |
0.332x | +43.29% |
| 2000-04-30 | €4.49 Billion ≈ $5.25 Billion |
€1.04 Billion ≈ $1.22 Billion |
0.232x | +86.22% |
| 1999-04-30 | €3.65 Billion ≈ $4.27 Billion |
€455.30 Million ≈ $532.29 Million |
0.125x | -56.84% |
| 1998-04-30 | €2.04 Billion ≈ $2.39 Billion |
€590.10 Million ≈ $689.89 Million |
0.289x | +8.73% |
| 1997-04-30 | €1.75 Billion ≈ $2.04 Billion |
€463.60 Million ≈ $542.00 Million |
0.265x | -5.09% |
| 1996-04-30 | €1.79 Billion ≈ $2.09 Billion |
€500.50 Million ≈ $585.14 Million |
0.280x | -3.56% |
| 1995-04-30 | €1.33 Billion ≈ $1.56 Billion |
€387.20 Million ≈ $452.68 Million |
0.290x | -14.39% |
| 1994-04-30 | €1.05 Billion ≈ $1.23 Billion |
€356.90 Million ≈ $417.25 Million |
0.339x | -2.20% |
| 1993-04-30 | €841.50 Million ≈ $983.80 Million |
€291.50 Million ≈ $340.79 Million |
0.346x | +82.24% |
| 1992-04-30 | €796.50 Million ≈ $931.19 Million |
€151.40 Million ≈ $177.00 Million |
0.190x | +2.58% |
| 1991-04-30 | €683.20 Million ≈ $798.73 Million |
€126.60 Million ≈ $148.01 Million |
0.185x | -6.13% |
| 1990-04-30 | €541.00 Million ≈ $632.49 Million |
€106.80 Million ≈ $124.86 Million |
0.197x | -- |
About Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor sy… Read more